Phase 3 Tuberculosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 21 years or older
- People who have been receiving tuberculosis (TB) treatment for 14 days or fewer, or who are about to start standard TB treatment
- People with confirmed TB in the lungs, shown by positive laboratory test results (such as a smear test, a DNA-based test, or a culture test)
- People whose chest X-ray shows TB affecting the lungs with one or more cavities (holes or hollow areas in the lung tissue)
- People who are able to give their informed consent to participate
Who may not be able to join:
- People who also have HIV
- People who have had TB in the lungs before
- People with serious, pre-existing lung conditions such as pulmonary fibrosis, bronchiectasis, chronic obstructive pulmonary disease (COPD), or lung cancer
- People who are pregnant or breastfeeding
- People with known allergies to tetracycline-type antibiotics
- People currently taking certain medications — including retinoic acid, neuromuscular blocking agents, or pimozide — that may increase the risk of drug side effects
- People with an autoimmune disease or who are taking medications that suppress the immune system
- People who have used another experimental drug, vaccine, or medical device within the past 182 days (roughly 6 months), or who plan to do so during the trial
- People already enrolled in another clinical trial involving a systemic drug or a procedure affecting the lungs
- People with evidence of severe depression, schizophrenia, or mania
- People whose liver function results (ALT) are more than 3 times above the normal upper limit
- People whose kidney function results (creatinine) are more than 2 times above the normal upper limit
- People whom the lead trial doctor believes are unwilling or unlikely to follow the full trial requirements, or who are considered to be at significantly increased risk of a harmful outcome
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Catherine Ong, MRCP PhD, National University Hospital, Singapore
Phone: +65 6908 2222
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Forced expiratory volume in 1 second (FEV1) at 26 weeks measured by spirometry
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.